{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:26:00Z","timestamp":1788193560702,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Specific antimigraine medications (dihydroergotamine (DHE), triptans) have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Quantify the risk of prematurity, low birth weight (LBW), major congenital malformations (MCM), and spontaneous abortions (SA) associated with gestational use of DHE or triptans in a privately insured cohort of pregnant women in the US.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cohort study within the US Merative MarketScan Research Database (2011\u20132021), composed of a nationally representative sample of patients with employer-provided health insurance. Four independent analyses were conducted to assess the risk of 1) prematurity (&amp;lt;37 weeks of gestation), 2) LBW (birth weight &amp;lt;2,500\u00a0g), 3) MCM, and 4) clinically detected SA. Exposure was defined dichotomously as use of DHE or triptan during pregnancy. Generalized estimation equations (GEE) were built to quantify the associations taking into account potential confounders including maternal migraine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 767,994 pregnant women met eligibility criteria and were included in the analyses on prematurity, LBW, and MCM; 11,121 cases of SA were identified and analyzed. One hundred and eighty-nine (189 (0.02%)) were exposed to DHE (all in the first trimester), and 4,309 (0.56%) to triptans. Adjusting for potential confounders including maternal migraine, DHE was not associated with a statistically significant risk of prematurity (adjusted RR (aRR) 1.17, 95%CI 0.14, 9.74), LBW (aRR 7.76, 95%CI 0.99, 60.83), MCM (aRR 2.27, 95%CI 0.97, 5.29), or SA (aOR 3.19, 95%CI 0.98, 10.38); DHE was associated with an increased risk of septal defects. All estimates showed increased risk but were unstable. Similarly, triptan use was not associated with any of the studied outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussions and Conclusions<\/jats:title><jats:p>After considering maternal migraine and other potential confounders, DHE (first trimester) and triptan exposure during pregnancy were not statistically significantly associated with an increased risk for prematurity, LBW, MCM, or SA. Findings on septal defects could be due to chance, and need replication.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1481378","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T08:59:37Z","timestamp":1734425977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-migraine medications safety during pregnancy in the US"],"prefix":"10.3389","volume":"15","author":[{"given":"A.","family":"B\u00e9rard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Strom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/1753495X18769170","article-title":"Current concepts in migraine and their relevance to pregnancy","volume":"11","author":"Afridi","year":"2018","journal-title":"Obstet. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/practneurol-2019-002332","article-title":"Migraine: navigating the hormonal minefield","volume":"20","author":"Afridi","year":"2020","journal-title":"Pract. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/s0002-9378(16)38739-7","article-title":"Oxytocic and toxic actions of dihydroergotamine-45","volume":"64","author":"Altman","year":"1952","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrneurol.2015.29","article-title":"Pharmacological treatment of migraine during pregnancy and breastfeeding","volume":"11","author":"Amundsen","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00228-016-2127-9","article-title":"Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women","volume":"72","author":"Amundsen","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e026690","DOI":"10.1136\/bmjopen-2018-026690","article-title":"Risk perception, beliefs about medicines and medical adherence among pregnant and breastfeeding women with migraine: findings from a cross-sectional study in Norway","volume":"9","author":"Amundsen","year":"2019","journal-title":"BMJ Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejogrb.2006.08.025","article-title":"Pregnancy complications and delivery outcomes in pregnant women with severe migraine","volume":"134","author":"Banhidy","year":"2007","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1365-2125.2007.02901.x","article-title":"Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth","volume":"64","author":"B\u00e1nhidy","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.clinthera.2007.05.003","article-title":"Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors","volume":"29","author":"Bar-Oz","year":"2007","journal-title":"Clin. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/j.1526-4610.2012.02172.x","article-title":"Dihydroergotamine (DHE) use during gestation and the risk of adverse pregnancy outcomes","volume":"52","author":"B\u00e9rard","year":"2012","journal-title":"Headache"},{"key":"B11","first-page":"156","article-title":"Magnitude of confounding caused by missing information in the studies on adverse pregnancy outcomes","volume":"18","author":"B\u00e9rard","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"19302","DOI":"10.1038\/s41598-021-97092-y","article-title":"Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes","volume":"11","author":"B\u00e9rard","year":"2021","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1526-4610.2012.02124.x","article-title":"Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment","volume":"52","author":"Dahl\u00f6f","year":"2012","journal-title":"Headache"},{"key":"B14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00415-021-10534-5","article-title":"A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project","volume":"269","author":"Dudman","year":"2022","journal-title":"J. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/s1701-2163(16)34177-9","article-title":"Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database","volume":"31","author":"Einarson","year":"2009","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"B16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0002-8703(03)00512-X","article-title":"The nested case-control study in cardiology","volume":"146","author":"Essebag","year":"2003","journal-title":"Am. Heart J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/s0899-9007(99)00218-x","article-title":"Regression to the mean","volume":"16","author":"Fitzmaurice","year":"2000","journal-title":"Nutrition"},{"key":"B18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12884-017-1399-0","article-title":"Patterns and predictors of analgesic use in pregnancy: a longitudinal drug utilization study with special focus on women with migraine","volume":"17","author":"Harris","year":"2017","journal-title":"BMC Pregnancy Childbirth"},{"key":"B19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11590370-000000000-00000","article-title":"Delivery outcome after maternal use of drugs for migraine: a register study in Sweden","volume":"34","author":"Kallen","year":"2011","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1111\/echo.14646","article-title":"Patent foramen ovale and atrial septal defect","volume":"37","author":"Kheiwa","year":"2020","journal-title":"Echocardiography"},{"key":"B21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamadermatol.2014.691","article-title":"Health care utilization patterns and costs for patients with hidradenitis suppurativa","volume":"150","author":"Kirby","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/bmj.327.7411.368","article-title":"Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study","volume":"327","author":"Li","year":"2003","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/head.12500","article-title":"Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis","volume":"55","author":"Marchenko","year":"2015","journal-title":"Headache"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/pds.3284","article-title":"Algorithms to estimate the beginning of pregnancy in administrative databases","volume":"22","author":"Margulis","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s12687-018-0384-2","article-title":"Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide","volume":"9","author":"Moorthie","year":"2018","journal-title":"J. Community Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1503\/cmaj.091208","article-title":"Use of antidepressants during pregnancy and the risk of spontaneous abortion","volume":"182","author":"Nakhai-Pour","year":"2010","journal-title":"CMAJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1503\/cmaj.110454","article-title":"Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion","volume":"183","author":"Nakhai-Pour","year":"2011","journal-title":"CMAJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/j.1468-2982.2009.01869.x","article-title":"Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study","volume":"29","author":"Nezvalova-Henriksen","year":"2009","journal-title":"Cephalalgia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1046\/j.1526-4610.2000.00003.x","article-title":"Pregnancy outcome following prescription for sumatriptan","volume":"40","author":"Olesen","year":"2000","journal-title":"Headache"},{"key":"B31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/eth.12713","article-title":"Generalized estimating equations: a pragmatic and flexible approach to the marginal GLM modelling of correlated data in the behavioural sciences","volume":"124","author":"Pek\u00e1r","year":"2018","journal-title":"Ethology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1211\/0022357991772321","article-title":"Simple O-acylated derivatives of lysergol and dihydrolysergol-I: synthesis and interaction with 5-HT2A, 5-HT2C and 5-HT1B receptors, and alpha1 adrenergic receptors","volume":"51","author":"Pertz","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"B33","volume-title":"Sander Greenland. Modern epidemiology","author":"Rothman","year":"2008"},{"key":"B34","first-page":"283A","article-title":"Effets de la dihydroergotamine sur l'hyperglyc\u00e9mie provoqu\u00e9e par l'\u00e9thylcarbamate chez le lapin [Effects of dihydroergotamine on hyperglycemia induced with ethylcarbamate in rabbits]","volume":"63","author":"Sassine","year":"1971","journal-title":"J. Physiol. Paris."},{"key":"B35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1212\/01.wnl.0000042477.63516.b2","article-title":"Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Silberstein","year":"2003","journal-title":"Neurology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0025-7125(16)31347-5","article-title":"Pregnancy and cardiovascular disease","volume":"61","author":"Ueland","year":"1977","journal-title":"Med. Clin. North Am."},{"key":"B37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/pds.1558","article-title":"Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women","volume":"17","author":"Vilain","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1481378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T08:59:41Z","timestamp":1734425981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1481378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":37,"alternative-id":["10.3389\/fphar.2024.1481378"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1481378","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"article-number":"1481378"}}